Callahan's re-election and short secondary life on the board was appalling nepotism/cronyism on Paul's part and no doubt some of that list amongst the presnet sellers. The crap I would have fought against had I been on the Board - clearly JDW not going to let that stuff happen anymore - and I would also be in the States pushing the consult group to get a good ATI partnerhsip and not simply spin it off for $250 million or so as Paul and the Prof did all those years ago for over $50 million USD with some of the ACI rights.
Bio-tech deals are picking up again in the US. It should be a seller's mkt over there in ATI. Our old mates J&J bought Ambrx Biopharma for $2 billion - we should have been invested in antibody drug conjugates clearly!
https://www.fiercebiotech.com/biotech/fierce-biotechs-quarterly-ipo-and-ma-roundup-q124
Callahan's re-election and short secondary life on the board was...
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.97M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 41.5¢ | $2.781K | 6.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 19945 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 26292 | 2 |
View Market Depth
| Last trade - 10.06am 02/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |